Abstract:Potential conflict of interest: Dr. Nguyen consults for, advises for, and received grants from Gilead, Bristol‐Myers Squibb, and Janssen. She consults for and received grants from Pfizer. Author names in bold designate shared co‐first authorship. TO THE EDITOR: We read with interest two articles recently published in Hepatology.1 Both studies showed that hepatocellular carcinoma (HCC) patients treated with all‐oral direct‐acting antiviral (DAA) regimens for hepatitis C virus (HCV) infection had lower sustained virological response 12 weeks after end of treatment (SVR12). In the study by Saberi et al., only 67% (14 of 21) of HCC patients achieved SVR12.1 In another study, all 5 patients who developed HCC within 6 months of therapy experienced virological relapse compared to 12 of 150 patients without HCC (100% vs. 8%; P < 0.0001).2 Similarly, Beste et al. showed that only 74.4% of patients with HCC achieved SVR12 compared to 91.1% in those without HCC.3 Prenner et al. also showed that patients with cirrhosis with active HCC (viable tumor on imaging) were almost 8 times more likely to fail HCV treatment than those without active HCC.4 Although the vast majority of the patients in these studies were non‐Asians,1 their results are consistent with our recent meta‐analysis of HCV genotype 1 (GT 1) patients from Asia, in which we showed a lower SVR12 in HCC patients treated with ledipasvir (LDV)/sofosbuvir (SOF) regimen (94.1% vs. 98.7% in non‐HCC patients; P = 0.001; Fig. 1A).5Figure 1: Pooled estimates of SVR rates in HCV genotype 1 patient with HCC from Asia. (A) With LDV/SOF regimen, patients with past history of HCC (n = 177) showed a lower SVR than those without HCC (n = 1,365; 94.1%; 95% confidence interval [CI], 89.9‐97.3 vs. 98.7%; 95% CI, 97.5‐99.6; P = 0.001). (B) With DCV/ASV regimen, patients with past history of HCC (n = 234) achieved a similar SVR to those without HCC (n = 1,064) (88.7%; 95% CI, 82.7‐93.6 vs. 88.0%; 95% CI, 86.0‐89.9; P = 0.9776).Though the most commonly used regimens in these studies were SOF‐based regimens and all showed lower SVR in HCC patients, results for subanalysis of the various individual DAA regimens were conflicting.1 In one subanalysis, SVR12 for HCC with HCV GT1 patients treated with paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) plus ribavirin (RBV) was 97.4%, which was similar to non‐HCC patients (92.3%); however, this finding should be interpreted with caution because this analysis only included 39 HCC patients.3 For GT1 patients treated with LDV/SOF ± RBV in the same study, the SVR12 in non‐HCC patients was significantly higher than those with HCC (93% vs. 76%), and this analysis included 303 HCC patients.3 In our meta‐analysis of patients treated with daclatasvir (DCV)/asunaprevir (ASV) with 234 HCC patients in Asia, SVR12 rates were similar for HCC and non‐HCC patients (88.7% vs. 88.0%; P = 0.98; Fig. 1B). Of note, although similar to SVR12 in non‐HCC patients treated with the same medications, SVR12 for DCV/ASV‐treated HCC patients was still lower than SVR12 for LDV/SOF‐treated HCC patients (94.1%).5 Further investigations with large, well‐controlled studies are needed to clarify the effect of HCC in response to different DAA regimens and to help identify the optimal regimen(s) for this population.

Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct‐acting antiviral agents

Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy

Alterations in Hepatocellular Carcinoma-Specific Immune Responses Following Hepatitis C Virus Elimination by Direct-Acting Antivirals

Direct-acting Antivirals Failed to Reduce the Incidence of Hepatocellular Carcinoma Occurrence in Hepatitis C Virus Associated Cirrhosis: A Real-World Study

Sustained Virologic Response to Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Hepatocellular Carcinoma Decreases the Effectiveness of Hepatitis C Antiviral Treatment: Do Direct‐acting Antiviral Regimens Matter?

Hepatitis C Virus - Related Hepatocellular Carcinoma in the Era of Direct - Acting Antiviral Agents

The development of hepatocellular carcinoma in HCV-infected patients treated with DAA: A comprehensive analysis.

Extrahepatic Cancer Risk in Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antivirals

A retrospective follow-up study of hepatitis C virus related cirrhosis treated with direct-acting antiviral agent

Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon Versus Direct-Acting Agents

Prognosis and incidence of immunological and oncological complications after direct-acting antiviral therapy for chronic hepatitis C

Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group

Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus

Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy

Effect of Direct Acting Antiviral Drugs on the Occurrence and Recurrence of Intra- and Extra-Hepatic Malignancies in Patients with Chronic Hepatitis C Virus Infection

DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C

Long-term Outcomes in Patients with Chronic Hepatitis C in the Current Era of Direct-Acting Antiviral Agents

Analyzing risk factors and developing a stratification system for hepatocellular carcinoma recurrence after interferon-free direct-acting antiviral therapy in chronic hepatitis C patients

Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b